GlassScriptPhysician profile
Levi R Stone
NPI 1700565785
$2,541.66
in general payments reported to CMS, 2019-2025
26 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $363 · 2024: $1,121 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.67 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $333.88 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Dexcom, INC. | $272.07 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $240.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $224.39 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $185.46 | 2023-2025 | |
| Astellas Pharma US INC | $181.68 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $145.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $120.89 | 2024-2025 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $117.59 | 2023-2025 | Sunosi, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.05 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $102.99 | 2023-2025 | Rexulti |
| Pfizer INC. | $96.80 | 2024 | |
| Tolmar, INC. | $81.74 | 2023-2024 | |
| Antares Pharma, INC. | $61.34 | 2024-2025 | Xyosted |
| Inspire Medical Systems, INC. | $50.01 | 2024-2025 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.53 | 2023 | Shingrix, Trelegy Ellipta |
| Viatris Specialty LLC | $26.67 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $23.68 | 2024 | Spravato |
| Halozyme INC | $22.70 | 2023 | |
| Corcept Therapeutics | $20.98 | 2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $19.23 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.28 | 2023 | Trintellix |
| Paratek Pharmaceuticals, INC. | $15.53 | 2024 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $14.19 | 2023 | Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $13.32 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.